Legal Status / FDA Liraglutide is FDA-approved and legally available by prescription in the United States under two brand names: Victoza (approved January 2010): Type 2 diabetes in adults and children aged 10+, dosed at 1.2 to 1.8 mg daily Saxenda (approved December 2014): Chronic weight management in adults with BMI of 30 or greater (or 27+ with a weight-related comorbidity) and adolescents aged 12+ with obesity, dosed at 3.0 mg daily Liraglutide is not a controlled substance and is classified as a prescription medication in all major markets

Usage Instructions Inject once weekly under the skin (abdomen, thigh, upper arm) Start at 0.25 mg weekly for 4 weeks, then increase as directed Doses may be raised to 0.5 mg, 1 mg, or 2 mg weekly Use at the same time each week (with or without food) Rotate injection sites to prevent skin irritation Side Effects Nausea, vomiting, diarrhea or constipation Loss of appetite Fatigue or headache Rare: pancreatitis, gallbladder problems, kidney injury, allergic reactions Increased risk of thyroid tumors in animal studies (not seen in humans) Side effects are often mild and improve with time
The effect is minor if stored consistently at 28C
Cortical bone demonstrated elevated porosity and reduced tibial cortical thickness, resulting in declines of 5.7%, 5.5%, and 5.2% in tibial compressive strength, stiffness, and apparent modulus, respectively